Podcasts about rifampin

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

In this conversation, Ryan Maves and Dennis discuss various aspects of tuberculosis, including recent outbreaks, public health implications, and treatment protocols. They delve into the complexities of managing tuberculosis in different contexts, particularly within military settings, and highlight the importance of public health initiatives like PEPFAR. The discussion also touches on the challenges posed by drug-resistant tuberculosis and the evolving landscape of health policy. In this conversation, Ryan Maves discusses the complexities of tuberculosis (TB), including its historical significance, transmission methods, diagnosis, treatment protocols, and the challenges posed by drug resistance. He emphasizes the importance of public health measures in managing TB outbreaks and reassures that most individuals with TB can recover with appropriate treatment. The discussion also highlights the role of good ventilation in reducing transmission risk and the need for awareness and screening in military and public health settings.TakeawaysTuberculosis outbreaks can be slow and complex, not immediate crises.Public health interventions are crucial for effective tuberculosis management.PEPFAR has saved millions of lives and is a significant achievement in global health.Drug-resistant tuberculosis presents unique challenges in treatment.Telemedicine can enhance the management of tuberculosis in remote settings.Understanding the transmission dynamics of tuberculosis is essential for prevention.Good ventilation and treatment protocols can mitigate tuberculosis risks.Public health policies can significantly impact disease control efforts.Collaboration and open dialogue are necessary for effective health policy.The importance of recognizing the long-term nature of tuberculosis management. Tuberculosis is a significant global health issue that has been impacted by the COVID-19 pandemic.HIV and tuberculosis have a close interaction, affecting incidence and outcomes.Active screening for tuberculosis is crucial, especially in military settings.Good ventilation and sunlight can significantly reduce the risk of TB transmission.Latent TB infection can progress to active disease if not treated promptly.The classic treatment regimen for active TB involves a combination of four drugs.Multi-drug resistant TB (MDR-TB) is a growing concern, particularly in certain regions.Rifampin is a key drug in TB treatment but has notable drug interactions.Most people with TB can recover with effective therapy, and treatment is often satisfying for healthcare providers.Public health measures are essential in managing TB outbreaks and ensuring community safety.Chapters00:00 Introduction and Personal Updates03:11 Understanding Tuberculosis Outbreaks06:00 Public Health and Policy Implications08:54 PEPFAR and Global Health Initiatives12:00 Tuberculosis in Military Contexts14:58 Diagnosis and Treatment of Tuberculosis18:01 Drug-Resistant Tuberculosis23:15 Understanding Tuberculosis: A Global Perspective27:43 Transmission and Infection: How TB Spreads33:31 Diagnosis and Screening: Identifying TB Cases41:41 Treatment Protocols: Managing Active and Latent TB51:29 Challenges of Drug Resistance in TB58:03 Public Health Response: Reporting and Managing OutbreaksThank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Drs. Henry “Chip” Chambers and Warren Rose join Dr. Megan Klatt to tackle rifampin dosing for gram-positive infections. In this episode, they break down rifampin synergy studies and discuss what is the optimal dosing of rifampin for challenging gram-positive bacterial cases, in particular Staphylococcus aureus infections with or without retained hardware/devices.   Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis. Open Forum Infect Dis. 2022 Oct 31;9(11):ofac583. doi: 10.1093/ofid/ofac583. PMID: 36408468. Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2023 Oct 3;78(10):2419-2427. doi: 10.1093/jac/dkad214. PMID: 37583062. Adjunctive Rifampin Following Debridement and Implant Retention for Staphylococcal Prosthetic Joint Infection: Is it Effective if not Combined With a Fluoroquinolone? Open Forum Infect Dis. 2022 Oct 31;9(12):ofac582. doi: 10.1093/ofid/ofac582. PMID: 36504699.

On episode #73 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 1/16/25 – 1/29/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation (Gastroenterology) Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients (Nature Communications) Insect-specific RNA viruses detection in Field-Caught Aedes aegypti mosquitoes from Argentina using NGS technology (PLoS Neglected Tropical Diseases) Bacterial Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis (NEJM) Impact of antibiotic treatment and predictors for subsequent infections in multidrug-resistant Pseudomonas aeruginosa catheter-associated asymptomatic bacteriuria (American Journal of Infection Control) Identification of the skip phenomenon among patients With Staphylococcus lugdunensis infective endocarditis (OFID) Emergence of infective endocarditis due to Serratia spp. (OFID) Reduction of vancomycin-associated acute kidney injury with montelukast (JID) Fungal The Last of US Season 2 (YouTube) Pulmonary co-infection of Pneumocystis jirovecii and Aspergillus species (OFID) Impact of fluconazoleon outcomes of patients with primary pulmonary coccidioidomycosis (CID) Parasitic Comparative outcomes of Babesiosis in immunocompromised and non-immunocompromised hosts (CID) Miscellaneous Hidradenitis suppurativa (LANCET) A severe case associated with mixed infections of Pasteurella multocida, Bacteroides pyogenes and Fusobacterium necrophorum due to a snow leopard bite (CMI: Clinical Microbiology and Infection) INSIDE-OUT: Introduction of speakers at IDWeek events (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In this episode of Breakpoints' Dosing Consult series, Drs. Chuck Peloquin and Gerry Davies join Dr. Megan Klatt to discuss rifampin dosing for mycobacterial infections. Hear from the experts on if higher doses are really better, toxicity thresholds, and the role of alternative rifamycins for patients with MTB and NTMs. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References: Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007 Oct; 2007(4): CD005159. doi: 10.1002/14651858.CD005159.pub2. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312. This podcast is powered by Pinecast.

This episode is sponsored by Medtronic.Painful diabetic peripheral neuropathy (DPN) can significantly impact a person with diabetes and their quality of life. Nalani Hunsaker PA-C, MCMSc, BC-ADM, a paid consultant for Medtronic, joins The Huddle to talk about Medtronic's spinal cord stimulation therapy option, how the procedure works, and its success in relieving pain from DPN. Please reach out to http://www.medtronic.com/dpnconnect to connect with a Medtronic representative today. If you would like to share more information with your patients check out http://www.medtronic.com/dpnpain References:1. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: A multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031 2. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: A prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684 3. Medtronic Pain Therapy Clinical Summary M221494A016 Rev B. United States; 2022. 4. van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983 5. Zuidema X et al. Long-term Evaluation of Spinal Cord Stimulation in Patients With Painful Diabetic Polyneuropathy: An Eight-to-Ten-Year Prospective Cohort Study. Neuromodulation. 2022 Dec 30:S1094-7159(22)01403-9. 6. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019;380(20):1895-19057. Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7.8. Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8 https://creativecommons.org/licenses/by/4.0/.9. Temel Y, Ackermans L, Celik H, et al. Management of hardware infections following deep brain stimulation. Acta Neurochir (Wien). April 2004;146(4):355-361.10. Pepper J. Zrinzo L, Mirza B, Foltynie T, Limousin P, Hariz M. The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg. 2013;91(1):56-65.11. Tolleson C, Stroh J, Ehrenfeld J, Neimat J, Konrad P, Phibbs F. The factors involved in deep brain stimulation infection: a large case series. Stereotact Funct Neurosurg. 2014;92(4): 227-233.12. Thrane JF, Sunde NA, Bergholt B, Rosendal F. Increasing infection rate in multiple implanted pulse generator changes in movement disorder patients treated with deep brain stimulation. Stereotact Funct Neurosurg. 2014;92(6):360-364.13. Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management [published correction appears in Neuromodulation. July 2017;20(5):516]. Neuromodulation. January 2017;20(1):31-50.14. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. March-April 2011;11(2):148-153.15. Falowski SM, Provenzano DA, XIa Y, Doth AH. Spinal Cord Stimulation Infection Rate and Risk Factors: Results From a United States Payer Database. Neuromodulation. February 2019;22(2):179-189.16. Clifton M, Quirouet A, Pizarro-Berdichevsky J, et al. Infection rate after sacral neuromodulation surgery: a review of 1033 InterStim procedures. J Urol. April 2016;195(4S):851.17. Bjerknes S, Skogseid IM, Sæhle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. August 14, 2014;9(8):e105288.18. Piacentino M, Pilleri M, Luigi Bartolomei L. Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochir (Wien). December 2011; 153(12):2337-2341.19. Hamani C, Lozano AM. Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248-251.20. Hayek SM, Veizi E, Hanes M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database. Neuromodulation. October 2015;18(7):603-608. 21. Bendel MA, O'Brien T, Hoelzer BC, et al. Spinal Cord Stimulator Related Infections: Findings From a Multicenter Retrospective Analysis of 2737 Implants. Neuromodulation. August 2017;20(6):553-557. 22. Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. July 2010;14(7):1081-1089.15 23. Chen T, Mirzadeh Z, Lambert M, et al. Cost of Deep Brain Stimulation Infection Resulting in Explantation. Stereotact Funct Neurosurg. 2017;95(2):117-124.24. Provenzano DA, Falowski SM, Xia Y, Doth AH. Spinal Cord Stimulation Infection Rate and Incremental Annual Expenditures: Results From a United States Payer Database. Neuromodulation. April 2019;22(3):302-310.25. Medtronic data on file: Economic Impact of Infection Related to Neuro-Stimulator Implant. Study report prepared for Medtronic prepared by Optum, 2018/01/03.26. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-2735. 27. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. May 16, 2019;380(20):1895-190528. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-273529. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. April 2021. doi:10.1001/jamaneurol.2021.0538 Spinal Cord Stimulation Brief Summary INDICATIONS Spinal cord stimulation (SCS) is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. CONTRAINDICATIONS Diathermy - Energy from diathermy can be transferred through the implanted system and cause tissue damage resulting in severe injury or death. WARNINGS Sources of electromagnetic interference (e.g., defibrillation, electrocautery, MRI, RF ablation, and therapeutic ultrasound) can interact with the system, resulting in unexpected changes in stimulation, serious patient injury or death. An implanted cardiac device (e.g., pacemaker, defibrillator) may damage a neurostimulator, and electrical pulses from the neurostimulator may cause inappropriate response of the cardiac device. Patients with diabetes may have more frequent and severe complications with surgery. A preoperative assessment is advised for some patients with diabetes to confirm they are appropriate candidates for surgery. PRECAUTIONS Safety and effectiveness has not been established for pediatric use, pregnancy, unborn fetus, or delivery. Avoid activities that put stress on the implanted neurostimulation system components. Recharging a rechargeable neurostimulator may result in skin irritation or redness near the implant site. ADVERSE EVENTS May include: undesirable change in stimulation (uncomfortable, jolting or shocking); hematoma, epidural hemorrhage, paralysis, seroma, infection, erosion, device malfunction or migration, pain at implant site, loss of pain relief, and other surgical risks. Adverse events may result in fluctuations in blood glucose in patients with diabetes. Refer to www. medtronic.com for product manuals for complete indications, contraindications, warnings, precautions and potential adverse events. Rx only. Rev 0422 TYRX™ Neuro Absorbable Antibacterial Envelope Brief Statement The TYRX™ Neuro Absorbable Antibacterial Envelope is intended to hold a vagus nerve stimulator, a spinal cord neuromodulator, a deep brain stimulator or a sacral nerve stimulator securely in order to create a stable environment when implanted in the body. The Neuro Antibacterial Envelope contains the antimicrobial agents Minocycline and Rifampin which, have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of a pulse generator. The Neuro Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, Rifampin, or absorbable sutures. The Neuro Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). This device is intended to be used in conjunction with vagus nerve stimulators or deep brain stimulators implanted in the infraclavicular fossa, or in conjunction with spinal cord neuromodulators or sacral nerve stimulators implanted laterally to the body midline and slightly superior to the gluteal region. The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because Minocycline and Rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the Neuro Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

Visit: https://nursing.com/140meds to request your free copy of "140 Must Know Meds" Generic Name isoniazide Trade Name INH Indication tuberculosis Action Inhibits synthesis of mycobacterial cell wall Therapeutic Class Antitubercular Pharmacologic Class none Nursing Considerations • can cause jaundice • may cause peripheral neuropathy, seizures, hepatitis • patient should avoid high amounts of tyramine (pickled meats, aged/smoked meats, alcohol, exotic/aged cheese) • monitor liver function tests • complete full course of therapy (6-12 months) • often used in combination with Rifampin

Can a common diabetes drug reduce the risk for long COVID? Find out about this and more in today's PV Roundup podcast.

Episode Notes Episode Notes Inspired by lamentations on Twitter, Drs. Bobbi Jo Stoner (@BobbiJo_Stoner), Jonathan Ryder (@JonathanRyderMD) and Sami El-Dalati join Dr. Jillian Hayes (@thejillianhayes) to hash out some of the controversies we encounter while managing infective endocarditis. Do we really need gentamicin and rifampin for all cases of staphylococcal prosthetic valve endocarditis? Where do oral antimicrobials fit into this disease state? Who should have a seat at the table to provide the most comprehensive care to these patients? Tune in for the answers to these questions and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: IDSA/AHA Infective Endocarditis Guidelines: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000296 Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis: https://pubmed.ncbi.nlm.nih.gov/36408468/ Twitter Poll – Gabe Vilchez (March 2021): https://twitter.com/IdVilchez/status/1372148761112240131?s=20&t=fYuyNWGmzZACWrpUb7Fp3g Survey of ID Physicians on Gent and Rifampin Use: https://pubmed.ncbi.nlm.nih.gov/32964063/ Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis: https://academic.oup.com/jac/article/52/5/820/760105 Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus: https://journals.asm.org/doi/abs/10.1128/AAC.34.12.2312 Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations: https://journals.asm.org/doi/abs/10.1128/aac.35.12.2611 Rifampin Combination Therapy for Nonmycobacterial Infections: https://journals.asm.org/doi/10.1128/CMR.00034-09 ARREST Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32456-X/fulltext Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study: https://pubmed.ncbi.nlm.nih.gov/32706879/ Nephrotoxicity of vancomycin, alone and with an aminoglycoside: https://pubmed.ncbi.nlm.nih.gov/2351627/ Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia: https://journals.asm.org/doi/10.1128/AAC.02483-18 Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments: https://academic.oup.com/ofid/article/7/1/ofz538/5691187 CERT Trial (in process): https://clinicaltrials.gov/ct2/show/NCT04886284 Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study: https://pubmed.ncbi.nlm.nih.gov/26872729/ A step-by-step guide to implementing a multidisciplinary endocarditis team: https://journals.sagepub.com/doi/10.1177/20499361211065596 Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement from the American Heart Association: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001090?cookieSet=1 Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319263/ A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity: https://academic.oup.com/ofid/article/9/7/ofac331/6625822 POET Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1808312 Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis: https://pubmed.ncbi.nlm.nih.gov/32785635/ Comparing right- and left sided injection-drug related infective endocarditis: https://pubmed.ncbi.nlm.nih.gov/33441950/ Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745005/ Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna: https://pubmed.ncbi.nlm.nih.gov/29659732/ Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis: https://academic.oup.com/ejcts/article/55/4/760/5126415 Bacteriological Outcome after Valve Surgery for Active Infective Endocarditis: Implications for Duration of Treatment after Surgery: https://academic.oup.com/cid/article/41/2/187/529954 Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study: https://academic.oup.com/cid/article/68/4/668/5039147 Sign of the Times: Updating Infective Endocarditis Diagnostic Criteria to Recognize Enterococcus faecalis as a Typical Endocarditis Bacterium: https://pubmed.ncbi.nlm.nih.gov/35262664/ Prevalence of colorectal disease in Enterococcus faecalis infective endocarditis: results of an observational multicenter study: https://pubmed.ncbi.nlm.nih.gov/31444092/ Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Download the cheat: https://bit.ly/50-meds  View the lesson:     Generic Name rifampin Trade Name Rimactane Indication tuberculosis Action inhibits RNA synthesis Therapeutic Class Antitubercular Pharmacologic Class rifamycins Nursing Considerations • can turn body fluids red • may cause diarrhea, nausea, vomiting, confusion • assess lung sounds and sputum characteristics • evaluate renal and liver function tests • instruct patient not to skip or double dose • must complete entire dose (6-12 month therapy)

On episode #15 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the previous two weeks, 10/27/22 – 9/9/22. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of Puscast! Links for this episode Clinical presentation and severity of adenovirus detection alone vs adenovirus co-detection with other respiratory viruses in US children (JPID) Effectiveness of different antimicrobial strategies for staphylococcal prosthetic joint infection (OFID) Clinical impact of ceftriaxone resistance in E. coli bloodstream infections (OFID)  Adjunctive Gentamicin and Rifampin in staphylococcal prosthetic valve Endocarditis (OFID) Diagnostic performance of physician gestalt for bacteremia in patients in the process of being admitted with suspected infection (OFID) Effectiveness of quinolone prophylaxis in pediatric acute leukemia and hematopoietic stem cell transplantation (OFID) Risk factors for Vancomycin drug reaction with Eosinophilia and Systemic symptoms syndrome (JAMA) Prospective evaluation of the fungitell 1>3 beta-d-glucan assay as a diagnostic tool for invasive fungal disease (Wiley) Safety and efficacy of a monoclonal antibody against malaria in Mali (NEJM) Hospitalizations associated with strongyloidiasis in the United States (CID)  Prophylactic benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs (PLOS NTD) Baker's dozen of top antimicrobial stewardship intervention publications for hospitalized patients (OFID) Baker's dozen of top antimicrobial stewardship intervention publications in non-hospital care settings in 2021 (OFID) Medical student debt and the US ID workforce (CID) Music is by Ronald Jenkees

Vanessa Nolet is a 29-year-old young woman from Quebec, Canada. She is working on finishing up a bachelor's degree in Healthcare Management. Prior to getting sick with Lyme disease, Ms. Nolet had a great life filled with friends and sports. She worked at a spa while going to college and was exposed to Freon during an accident which changed her life. Around this time, Ms. Nolet was bit by a tick and within a month she became very ill. She had chronic fatigue, whole body spasms, light sensitivity, body burning, ulcers, arthritis, irregular periods, autoimmune symptoms, and more. She visited many doctors, specialists, and hospitals in Canada before going to America for help where she was finally diagnosed. Nobody could figure out why she was sick. Some doctors misdiagnosed her with conditions such as Fibromyalgia, other pain disorders, and Lupus. Finally, at the age of 27, Ms. Nolet was diagnosed with Lyme disease in part thanks to Dr. Richard Horowitz's Multiple Systemic Infectious Disease Syndrome (MSIDS) questionnaire. She was treated with Doxycycline, Rifampin, Azithromycin, Naltrexone, AGE, and more with a specialist in Canada. If you would like to learn how a young woman from Canada fought for a root cause diagnosis and is now on the path to health, then tune in now! PS Johanna Laliberte special guest co-hosted this interview with Matt from Tick Boot Camp!

Grace Anderson is a 21-year-old Lyme disease advocate from the coast of Maine. She's currently studying mental health and human services. Ms. Anderson first became sick with symptoms of Lyme when she was 12 at a Taylor Swift concert with the following symptoms: dizziness, nausea, swollen feet, excessive sweating, and vomiting. These symptoms quickly subsided, but they came back a month later and never went away with the addition of migraines, fatigue, difficulty walking, full body pain, and body weakness. Ms. Anderson tested positive for Hashimoto's disease and the rest of her symptoms were dismissed as "just anxiety". Her health continued to decline, and she saw many doctors and specialists, including those at Boston Children's Hospital. Finally, Ms. Anderson's mother brought her to a naturopath when she was 16 where she was tested for Lyme, and it came back positive. She was also diagnosed with POTS and through trial and errors found a treatment that was very effective at controlling her symptoms. After making progress with her treatment, Ms. Anderson became very sick again a few years later and was diagnosed with Bartonella and active Lyme disease which likely was from a new tick bite. She used a wide variety of treatments including antibiotics like Doxycycline and Rifampin. If you'd like to learn more about a young woman who fought back against childhood Lyme disease and is now helping others in their healing journeys, then tune in now! PS Carly Taylor special guest co-hosted this interview with Matt from Tick Boot Camp!

Download the cheat: https://bit.ly/50-meds  View the lesson: https://bit.ly/IsoniazidNiazidNursingConsiderations    Generic Name isoniazide Trade Name INH Indication tuberculosis Action Inhibits synthesis of mycobacterial cell wall Therapeutic Class Antitubercular Pharmacologic Class none Nursing Considerations • can cause jaundice • may cause peripheral neuropathy, seizures, hepatitis • patient should avoid high amounts of tyramine (pickled meats, aged/smoked meats, alcohol, exotic/aged cheese) • monitor liver function tests • complete full course of therapy (6-12 months) • often used in combination with Rifampin

Episode 87: Latent TB Infection.  By Mariana Gomez, MD (Romulo Gallegos University School of Medicine, Carillion Clinic Infectious Disease), and Hector Arreaza, MD (Romulo Gallegos University School of Medicine, Rio Bravo Family Medicine Residency Program). Dr. Gomez explains how to screen for and treat Latent TB infection. Today is March 18, 2022.Dr. Mariana Gomez graduated from medical school at the Romulo Gallegos University in Venezuela. She completed her residency in Internal Medicine in St Barnabas Hospital, which is affiliated with the Albert Einstein School of Medicine, Bronx, New York. She then completed a fellowship in Infectious Diseases at Carilion Clinic, which is affiliated with Virginia Tech School of Medicine. She currently works in Virginia, United States.  This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. Some questions discussed during this episode: Who should be screened for latent TB infection? A CDC questionnaire can determine the risk for latent TB infection. Some patients who may be screened are those who resided for 1 month in a country with high TB prevalence, those who are currently immunosuppressed or planning immunosuppression in the near future (50 mg of prednisone or equivalent a day for 1 month), and those who had close contact with patients with TB infection (Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (cdc.gov)). The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.Screening Tests: Currently, there are two types of screening tests for LTBI in the United States: the tuberculin skin test (TST, also known as PPD) and the Interferon Gamma Release Assay (IGRA, brand names QuantiFERON®-TB and T-SPOT®.TB). The TST requires intradermal placement of purified protein derivative and interpretation of response 48 to 72 hours later. The induration is measured in millimeters. The induration is the palpable, raised, hardened area or swelling, not the erythema.IGRA requires a single venous blood sample, and the result is obtained in 1-2 days. Two types of IGRAs are currently approved by the US Food and Drug Administration: T-SPOT.TB (Oxford Immunotec Global) and QuantiFERON-TB Gold In-Tube (Qiagen). The CDC recommends screening with either test (TST or IGRA) but not both. IGRAs is preferred for patients who received a BCG vaccine (bacille Calmette–Guérin) or if they are unlikely to return for TST interpretation.Why should we screen for LTBI? How can we decide between Questionnaire only vs PPD vs QuantiFERON Gold? What is the next step in assessing asymptomatic individuals with positive PPD?A useful resource is the online TST/IGRA Interpreter (tstin3d.com). You can calculate the risk of latent TB infection and the risk of INH-induced hepatitis. How can we decide to treat LTBI? What are the recommended regimens? CDC recommends three preferred regimens. These are chosen for effectiveness, safety, and high treatment completion rates. These regimens are rifamycin-based. They are:INH+rifapentine for 3 months: once-weekly isoniazid plus rifapentine for adults and children older than age 2, regardless of HIV status.Rifampin for 4 months: daily rifampin.INH+rifampin for 3 months: daily isoniazid plus rifampin. ____________________________Now we conclude our episode number 86 “Latent TB Infection.” Dr. Gomez taught us how to screen and treat latent TB infections. Remember to screen only those who are at risk of TB infection. Once you get a positive screen test, select the patients who will receive treatment of LTBI to prevent reactivation of TB infection. You have at least 4 regimens to treat LTBI. The regimens that include rifamycin are recommended by the CDC. Even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created for educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza and Mariana Gomez. Audio edition: Suraj Amrutia. See you next week! _____________________References: Latent Tuberculosis Infection: Screening, September 06, 2016,  United States Preventive Services Taskforce, uspreventiveservicestaskforce.org. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening. Lewinsohn, David M., et al, Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017;64(2):e1–e33, Infection Diseases Society of America, https://www.idsociety.org/globalassets/idsa/practice-guidelines/official-american-thoracic-society.infectious-diseases-society-of-america.centers-for-disease-control-and-prevention-clinical-practice-guidelines-diagnosis-of-tuberculosis-in-adults-and-children.pdf.   Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69(No. RR-1):1–11. DOI: http://dx.doi.org/10.15585/mmwr.rr6901a1. The Online TST/IGRA Interpreter, McGill University and McGill University Health Center Montreal Quebec, Canada, http://tstin3d.com/. 

In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:DHHS testing and treatment recommendations for HBV in patients with HIVData suggesting that tenofovir alone may not suppress HBV in all PWHData from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBVData for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV activeData showing that lamivudine alone is associated with resistance in patients with HIV/HBVDiscussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfectedRecommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfectionData from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIVRecommendations from the EACS guidelines on what ART regimens are recommended with TB/HIVDrug-drug interaction considerations between ART and TB treatmentDiscussion of the prevention and management of TB-associated IRISPresenters:Daria Podlekareva, MD, PhDCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark  Mark S. Sulkowski, MDProfessor of MedicineMedical Director, Viral Hepatitis CenterChief, Infectious DiseaseJohns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with slides:https://bit.ly/3zHySMOSee the entire program at:https://bit.ly/2TXTYWx

Show notes at pharmacyjoe.com/episode633. In this episode, I’ll discuss how rifampin affects hydromorphone levels. The post 633: How much does rifampin affect hydromorphone levels? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode633. In this episode, I’ll discuss how rifampin affects hydromorphone levels. The post 633: How much does rifampin affect hydromorphone levels? appeared first on Pharmacy Joe.

Episode 60: Variety of Topics.  Gabrielle Robinson (MS3) discusses with Dr Arreaza these topics: IsoPSA, 3HP for LTBI, shingles vaccine, and DELC.Introduction: You will hear a conversation between Gabrielle Robinson, a 3rd year medical student, and Hector Arreaza. They discussed 4 articles about topics that are relevant to current clinical practice in family medicine.This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home.Variety of Topics. By Gabrielle Robinson, MS3, Ross University School of Medicine, and Hector Arreaza, MD.  The IsoPSA testH: Cleveland Clinic published this article in July 2020[1]. G: According to that article, the IsoPSA test is a new clinically relevant screen for prostate cancer. The data suggests that ISoPSA can potentially decrease unnecessary prostate biopsies by 45%. The IsoPSA evaluates changes in the structure of PSA rather than measuring the concentration of PSA.  G: IsoPSA is meant to be used in patients who are over 50 years old with PSA > 4ng/mL that have not had a previous diagnosis for prostate cancer or are under surveillance.H: Is PSA a bad screening test?G: Measuring the concentration of PSA has proven to be a less sensitive screening tool because PSA is specific for tissues and nonspecific for cancer. This means that a high PSA does not necessarily mean cancer is present.  The PSA can be elevated due to a multitude of reasons including but not limited to prostatitis, benign prostatic hyperplasia, etc.  Unfortunately, this has led to the overdiagnosis of low-grade cancers that were in fact benign conditions. However, PSA is an effective tool for monitoring of recurrence of prostate cancer and it reduces the need for treatment of metastatic disease.H: As a reminder, screening for prostate cancer in asymptomatic individuals by using PSA is a grade D recommendation from the USPSTF. D means “Do not do it!” However, IsoPSA is not included in that recommendation. We'll see if evidence suggests IsoPSA as an alternative in the future.  3HP for latent TB infection treatmentH: This information was published by CDC on June 28, 2018. G: Previously, the treatment for latent TB included 3–9 months of DAILY Isoniazid (INH) or Rifampin (RIF), either alone or combined.  Now, new data according to CDC recommends that INH-RPT (isoniazid-rifaPENtine) treatment once a week for 12 weeks (AKA 3HP regimen) is adequate in controlling the reactivation of latent TB[2].H: RifaPEntine is not Rifampin.G: It is also worth mentioning that this treatment is also approved for patients 2-11 years of age as well as patients who have HIV/AIDS who are currently taking anti-retroviral.H: Currently, the regimens for LTBI treatment are: -Monotherapy with INH for 6-9 months-Monotherapy with Rifampin daily for 4 months-Combinations: INH-Rifampin daily for 3 months (3HR therapy), and INH-RifaPENTINE weekly for 3 months (3HP therapy). Shingles vaccine may reduce risk of strokeG: Why do we think having shingles increases risk of stroke in the first place? The mechanism is not well understood but there is a strong index of suspicion that the inflammation resulting from the outbreak plays a significant role.  H: So, you read a study, a chart review published by the American Heart Association, tell us about it.In this study, patients who received the shingles vaccine (live vaccine) were compared to patient who did NOT receive the vaccine. The results showed that getting the shingles vaccine decreased the risk of stroke by 16%.  The types of strokes that were decreased included hemorrhagic stroke which was decreased by 12% and ischemic stroke that was decreased by 18%.  The age range for which this was most effective is 66 to 79 years of age and is worth mentioning that patients under 80 years of age had a decreased risk in stoke by 20% while the patients over 80 years old were decreased by about 10%[3]. Diagonal Ear Lobe Crease: An Association with CADH: Last week we got this information from Dr Cobos, a Kern Medical hematologist. G: Diagonal Ear Lobe Crease (DELC) also known as Frank's sign, is a crease in the ear lobe that is associated with increased risk of coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Although the pathophysiology of this sign is not yet understood, there has been a grading system set in place that is linked to the incidence of cardiovascular events based on length, depth, bilateralism, and inclination according to Stanford Medicine. The classifications are as follows:Unilateral incomplete – least severeUnilateral completeBilateral complete – Most severe Other classification (not associated with increased cardiovascular events):Grade 1 – wrinklingGrade 2a – Superficial crease (floor of sulcus visible)Grade 2b – crease greater than 50% across earlobeGrade 3 – deep cleft across whole earlobe (floor of sulcus not visible) H: As a curious fact, Steven Spielberg and Mel Gibson have the DELC.  Conclusion: Now we conclude our episode number 60 “Variety of Topics.” Future Dr Robinson presented a summary of four interesting articles she read. She explained that IsoPSA may be an alternative for screening for prostate cancer in the future, and she reminded us of the weekly treatment of latent tuberculosis infection with INH and rifaPENtine (also known as 3HP treatment for LTBI). There was a decrease in stroke risk in patients who received shingles vaccine, according to a study published by the American Heart Association in 2020, and the Diagonal Ear Lobe Crease sign was mentioned as a possible association with cardiovascular risk. Even without trying, every night you go to bed being a little wiser. Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RBresidency@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza and Gabrielle Robinson. Audio edition: Suraj Amrutia. See you next week! ____________________________References:  The IsoPSA Test Is Available, and It Could Change the Diagnostic Paradigm for Prostate Cancer, Consult QD, Cleveland Clinic, Jul 7, 2020, https://consultqd.clevelandclinic.org/the-isopsa-test-is-available-and-it-could-change-the-diagnostic-paradigm-for-prostate-cancer/ CDC Releases Updated Recommendations for Treatment of Latent TB Infection, Centers for Disease Control and Prevention, June 28, 2018, https://www.cdc.gov/nchhstp/newsroom/2018/treatment-of-latent-TB-infection.html Shingles vaccine may also reduce stroke risk, American Heart Association, February 12, 2020, https://newsroom.heart.org/news/shingles-vaccine-may-also-reduce-stroke-risk Frank's Sign - Diagonal earlobe crease (DELC), Stanford Medicine 25, July 2, 2015, https://stanfordmedicine25.stanford.edu/blog/archive/2015/what-is-the-name-of-this-sign.html 

This episode covers rifampin!

Este es Medical commons un podcast de la academia de atención Primaria para el mejoramiento de la calidad de la atención en salud de las Américas, a continuación intentaremos dar una revisión sistemática por los temas mayormente  preguntados en los exámenes de residencias médicas en Colombia y que frecuentemente son motivo de consulta en atención primaria.  Todas las decisiones médicas y recomendaciones aquí expresadas deben de ser comparadas con la información académica oficial y jamás deben de ser tomados como un absoluto, los actos médicos derivados de estos audios son responsabilidad de aquellos que ejercen. La mayoría de los hospitales tienen un comité de medicamentos compuesto por médicos y farmacéuticos que se aseguran de que el uso de rifampicina se realice en circunstancias controladas. De hecho, en muchos hospitales, es necesario solicitar el permiso del experto en enfermedades infecciosas o del farmacéutico antes de utilizar vancomicina.    Referencia Beloor Suresh A, Wadhwa R. Rifampin. [Updated 2020 May 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557488    Este podcast se distribuye bajo los términos de Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), que permite su uso, duplicación, adaptación, distribución y reproducción en cualquier medio o formato, siempre que otorgue el crédito apropiado al autor o autores originales y la fuente, se proporciona un enlace a la licencia Creative Commons, y se indican los cambios realizados.

WARFARIN. Introduction , mechanism of action , Side Effects :- BLEEDING , RETROPERITONEAL HEMORRHAGE ,PURPLE TOE SYNDROME , OSETEOPOROSIS RELATED BONE FRACTURE .. CLINICAL CONSIDERATIONS:- FIRST TRIMESTER - FETAL WARFARIN STNDROME - Nasal hypoplasia , narrowed Nasal bridge , other limbic and cardio abornmalities , SECOND & THIRD TRIMESTER : CNS abornmalities , ocular defects , seizures , low birth weight. ... ANTIDOTE : PHYTOMENADIONE (VIT k) CYP P450 INHIBITORS: macrolides, Flucanazole , Protease inhibitors. CYP 450 INDUCERS : Phenytoin , Carbamazepine, Rifampin .. insta id : Srinath Kalepu .. LINKEDIN : Kalepu Srinath

Tuberculosis Meds. Rifampin, INH, isoniazid, Pyrazinamide, Ethambutol Free quiz & full course at https://Simplenursing.com/nursing-school  Pharmacology Master Class - 100 videos not on YouTube - Try it for Free!    Pharmacology Master Class - Try it for Free: https://Simplenursing.com/nursing-school  100 videos not on YouTube    FREE Access to new app + 1,000 videos not on youtube!  https://Simplenursing.com/nursing-school   NCLEX FREE TRIAL:  https://simplenursing.com/NCLEX   STAY IN TOUCH

Mary T. Bessesen, MD joins JAMA Network editors to discuss a cohort study that compares amputation and mortality rates among patients treated in the Veterans Health Administration for diabetic foot osteomyelitis with and without rifampin. Read the article here: https://ja.ma/37IBIT8. JNO Live is a weekly broadcast featuring conversations about the latest research being published in JAMA Network Open. Follow us on Facebook, Twitter and YouTube for details on the next broadcast.

Editor in Chief Fred Rivara and Deputy Editor Steve Fihn discuss research published in JAMA Network Open in November 2019.

Rifampin is classified as an antibiotic and an antituberculosis agent. It primarily works by inhibiting bacterial RNA polymerase. While not extremely common, rifampin is well known to cause hepatic dysfunction. You should remind patients who are taking rifampin that it can alter the color of tears, sweat, saliva and urine. It can change these fluids to a reddish/brown color. Rifampin is very well known for causing drug interactions. It is an enzyme inducer that can reduce the concentrations of numerous medications such as warfarin, apixaban, cyclosporin, levothyroxine, and oral contraceptives to name a few. Rifampin can be used to help prevent meningococcal infection. Learn more on rifampin by listening to this podcast!

On this episode, we discuss the recent Arizona House Bill 2548 that will allow pharmacists more prescribing authority. We also review RIPE therapy (rifampin, isoniazid, pyrazinamide, and ethambutol) as well as some other treatment options available for latent and active tuberculosis.  Go check out Rx Coffee for all your caffeine needs! https://drinkrxcoffee.com If you have any questions, reach out to us on any of the following: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.  

In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.

The post Rifampin (Rimactane) Nursing Pharmacology Considerations appeared first on NURSING.com.

En el programa de hoy hablamos de tuberculosis latente y comentamos dos articulo publicados esta semana en el New England Journal of Medicine sobre el tratamiento de la misma con rifampicina, la cual promete convertirse en la droga de elección para esta indicación.    Referencias:   Dick Menzies y colaboradores. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Eng J Med. Agosto 2, 2018. T Dallio y colaboradores.  Safety and Side Effects of Rifampin versus Isoniazid in Children. N Eng J Med. Agosto 2, 2018. Ann O’Garra y colaboradores. The Immune Response in Tuberculosis. Ann Rev Immunol. 2013.   Frase de la Semana:   La tomamos de Albert Einstein nacido el 14 de marzo de 1879 – y fallecido el 18 de abril de 1955. físico teórico nacido en Alemania que desarrolló la teoría de la relatividad, la cual, junto a la teoría de mecánica cuántica, forman dos pilares de la física moderna.   “Cuando te mueres, no sabes que estás muerto, no sufres por ello, pero es duro para el resto. Lo mismo pasa cuando eres imbécil”